COMP <GO>
PRCT vs IRMD // GROSS PROFIT MARGIN
PROCEPT BioRobotics Corporation (NASDAQ) VS. iRadimed Corporation (NASDAQ) • 15-METRIC TALLY: PRCT 3
— IRMD 7
▲ GROSS PROFIT MARGIN LEADER: IRMD
LAST: $20.30 (+0.50%) • MKT CAP: $1.16B
gross-margins
63.70%
LAST: $85.74 (+2.16%) • MKT CAP: $1.10B
gross-margins
76.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRCT VS. IRMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRCT | IRMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 63.70% | 76.70% | -13.00 | IRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 37.70% | -72.70 | IRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 31.9x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.02% | 1.57% | -6.59 | IRMD | /fcf-yield <GO> |
| Operating Margin | -33.70% | 31.20% | -64.90 | IRMD | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 26.80% | -26.80 | IRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 37.20% | 14.40% | +22.80 | PRCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.37% | -1.37 | IRMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.98 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | IRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.7 | 25.6 | +25.08 | PRCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 41.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.16B | $1.10B | $66.3M | PRCT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRCT REV | IRMD REV | PRCT GROSS % | IRMD GROSS % | PRCT FCF | IRMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $308.1M | $83.8M | 63.7% | 76.7% | -$58.3M | $17.2M |
| FY 2024 | $224.5M | $73.2M | 61.1% | 76.9% | -$103.6M | $17.6M |
| FY 2023 | $136.2M | $65.6M | — | — | -$108.0M | $13.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRCT // BETA —
IRMD // BETA —